Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 31, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
6025
Shown on this page
12
Current sort
Recently updated
Condition scope
Obesity
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Obesity studies are organized in the registry

Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Obesity. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 529–540 of 6,025 matching trials for Obesity.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Pain, Back, Obesity, Morbid, Type 2 Diabetes
Interventions
Research electrode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Obesity, Overweight
Interventions
NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Type 2 Diabetes in Black Emergent Adult

NCT06848244
Conditions
Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating, Obesity
Interventions
Appetite Awareness Training (AAT), Diabetes Prevention Program (DPP)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity, Cancer, Physical Activity, Cancer Survivorship, Diet
Interventions
AYA WELL Intervention, Self-Guided
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy, Obesity, Adolescent Obesity, Diabetic Kidney Disease
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40, Renal Biopsy, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 26 Years
Enrollment
57 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Oxnard, California • Stamford, Connecticut • Atlanta, Georgia + 8 more
Conditions
Obesity, Childhood
Interventions
Topiramate Tablets
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Glucose Intolerance
Interventions
High Intensity Interval Training (HIIT), Moderate-intensity continuous training (MICT)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
PreDiabetes, Prediabetic State, Overweight and Obesity
Interventions
Empagliflozin, Multivitamin-Placebo
Drug
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Corvallis, Oregon
Conditions
Healthy, Obesity, Overweight
Interventions
LY3549492
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

About this Obesity clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Obesity.